• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Managing malignant conjunctival lesions

Article

Ophthalmologists can be involved in managing patients with malignant conjunctival lesions, most often-pigmented conjunctival lesions, primary acquired melanosis, conjunctival melanoma, conjunctival and corneal squamous neoplasia, and squamous cell carcinomas. Nicholas T. Iliff, MD, described how these pathologies are best approached. Dr. Iliff is Maurice Bendann, Violet Bendann, Constance Bendann and Charles E. Iliff Professor of Ophthalmology, professor of plastic surgery, and director - oculoplastic surgery, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.